Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients. [electronic resource]
Producer: 20170623Description: 938-947 p. digitalISSN:- 1097-0215
- Adult
- Antineoplastic Agents, Hormonal -- therapeutic use
- Breast Neoplasms -- chemistry
- Combined Modality Therapy
- Feasibility Studies
- Female
- Genes, erbB-2
- Heterocyclic Compounds, 1-Ring -- analysis
- Humans
- Immunoconjugates -- administration & dosage
- Lutetium -- administration & dosage
- Mastectomy
- Middle Aged
- Molecular Targeted Therapy
- Neoplasm Metastasis
- Neoplasm Proteins -- antagonists & inhibitors
- Pilot Projects
- Radioimmunotherapy
- Radioisotopes -- administration & dosage
- Receptor, ErbB-2 -- antagonists & inhibitors
- Single Photon Emission Computed Tomography Computed Tomography
- Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
- Tamoxifen -- therapeutic use
- Tissue Distribution
- Trastuzumab -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.